Skip to main
PGEN
PGEN logo

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen Inc is positioned for significant growth, particularly with the anticipated launch of its PRGN-2012 product in the second half of 2025, supported by upgraded GMP facilities that enhance manufacturing capacity. The company projects risk-adjusted revenues for PRGN-2012 to reach $93 million in 2026, with an impressive increase to $969 million by 2033, driven by strong Phase 2 data and a solid understanding of the market's needs. Additionally, adjustments in their financial model, including a revised patient population forecast and an increased annual pricing estimate, further underscore a positive outlook for the company's financial performance in the coming years.

Bears say

Precigen Inc has faced challenges in its financial performance, reflected in growing operational losses that raise concerns regarding its business sustainability in the competitive biotechnology sector. The company's reliance on exclusive collaborations for revenue generation poses a risk, as any setbacks in securing or maintaining partnerships could significantly impact its revenue streams. Additionally, the fluctuating nature of technology access fees and royalties underscores the volatility in the company’s income, further contributing to a negative outlook.

Precigen (PGEN) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 6 analysts, Precigen (PGEN) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.